Tysabri Or Not Tysabri?
This article was originally published in RPM Report
Executive Summary
FDA is facing one of its toughest decisions on whether to let Biogen Idec/Elan's multiple sclerosis drug Tysabri back on the market. The agency has just begun its re-review of the supplemental BLA and is in the process of determining whether to grant the application expedited priority review.